Sava, a health monitoring company based in London, UK, has successfully raised $8 million in Seed funding. The funding round was led by Balderton Capital and Exor Ventures. This investment will be utilized to expand Sava’s team, design a new product line with manufacturing capabilities, and demonstrate the platform’s clinical performance.
Founded by Renato Circi and Rafael Michali, Sava is focused on developing a wearable biosensor platform capable of detecting molecules just beneath the skin. The company’s innovative microsensor technology aims to provide real-time monitoring of biomarkers in the body, with an initial focus on glucose levels. This technology promises pain-free and real-time insights for users.
Sava recently received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct clinical trials on patients with diabetes. These trials, set to begin soon with investigators from the Universities of Oxford and Cambridge, will help validate Sava’s technology on a larger scale.
Renato Circi, co-founder of Sava, stated, “At Sava, we are tackling preventable illness by building a new operating system for health monitoring. Our microsensor will revolutionize healthcare by making world-leading monitoring technology available to all. With this capital, we can accelerate our goal of creating a new paradigm for healthcare—preventative, personalized, and painless.”
James Wise, Partner at Balderton Capital, commented, “This could be the defining product in personal health monitoring in the coming decade and an essential tool for patients and clinicians in diagnosing and treating many chronic diseases as well. Renato and Rafael have a compelling user-centric vision to revolutionize chronic disease management and preventative care, and the credibility and knowledge to execute in this vital area.”
Noam Ohana and Ileana Pirozzi of Exor Ventures added, “Sava’s unique approach and novel technology underline its potential to become a foundation of a new healthcare system. It offers a platform that addresses the needs of both patients and healthcare systems and which will allow other companies to build upon.”
This round brings Sava’s total funding to $13 million, enabling further expansion of the team, enhancement of product lines, and comprehensive demonstration of their clinical performance capabilities.